# BRE12-158 (NCT02101385)

> Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02101385
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Bryan Schneider, MD
- Conditions: Malignant Neoplasm of Breast; Breast Cancer
- Interventions: Genomically Directed Monotherapy; Observation/Standard Therapy
- Enrollment: 193
- Primary outcome: Percentage of Participants With Two-Year Disease-Free Survival (DFS)

## Indexed commentary on BRE12-158 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=bre12-158-nct02101385